Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024 [Yahoo! Finance]
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Yahoo! Finance
"The Exact Sciences team is constantly innovating to help close the screening gap," said Kevin Conroy, chairman and CEO, Exact Sciences. "The insights that led to this innovation reflect our understanding of the biology of cancer and the power of our scientific capabilities. We took a unique scientific approach to developing this test by combining a novel panel of markers. This led to data that improve upon what we previously thought was possible with a blood-based colorectal cancer screening test." To optimize the final test algorithm, Exact Sciences designed a study to simulate the screening population in the United States and better predict real-world, prospective performance of a novel test. The study consisted of more than 3,000 blood samples, including approximately 2,900 blinded, prospectively collected samples from the pivotal BLUE-C study. This analysis was prespecified with the U.S. Food and Drug Administration (FDA) and the samples will be excluded from the final clinica
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Exact Sciences gains 6% following data on blood-based colorectal cancer test [Seeking Alpha]Seeking Alpha
- ESMO 2024: Exact Sciences unveils results from cancer algorithm trial [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024Business Wire
- Exact Sciences Co. (NASDAQ: EXAS) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $75.00 price target on the stock.MarketBeat
- Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Piper Sandler from $75.00 to $85.00. They now have an "overweight" rating on the stock.MarketBeat
EXAS
Earnings
- 7/31/24 - Beat
EXAS
Sec Filings
- 9/19/24 - Form 4
- 9/18/24 - Form 144
- 8/6/24 - Form 4
- EXAS's page on the SEC website